Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 9/20 | 0.55 |
| ▸ | BCHE known ✓ | P06276 | 9/20 | 0.51 |
| ▸ | SCN4A known ✓ | P35499 | 2/20 | 0.47 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.45 |
| ▸ | BACE1 | P56817 | 8/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20597421 | 1.00 | ACHE (0.55) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| Hydrochloric Acid SCHEMBL1373413 | 1.00 | ACHE (0.55) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| Hydrochloric Acid SCHEMBL22500017 | 1.00 | ACHE (0.55) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| Hydrochloric Acid SCHEMBL29414409 | 1.00 | ACHE (0.55) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| Hydrochloric Acid SCHEMBL1847744 | 1.00 | ACHE (0.55) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| Hydrochloric Acid SCHEMBL1373407 | 1.00 | ACHE (0.55) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| Hydrochloric Acid SCHEMBL2148084 | 1.00 | ACHE (0.55) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| SCHEMBL1993388 | 0.98 | ACHE (0.57) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| SCHEMBL14018259 | 0.98 | ACHE (0.57) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| SCHEMBL352022 | 0.98 | ACHE (0.57) | ACHEBCHEBACE1ALDH1A1SCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119574716-A | Method for detecting impurities in (3R, 4R) -1-benzyl-N, 4-dimethylpiperidin-3-amine dihydrochloride | 南京药石科技股份有限公司 | 2025-03-07 | — | — | CN | claimed |
| CN-113930404-B | Method for synthesizing chiral tofacitinib citrate intermediate by enzymatic method | 浙江乐普药业股份有限公司 | 2023-10-13 | — | — | CN | claimed |
| CN-115808472-A | Method for analyzing and detecting impurity BMPA-3 in R-BMPA | 江苏万邦生化医药集团有限责任公司 | 2023-03-17 | — | — | CN | claimed |
| CN-112213402-B | Method for detecting (3R, 4R) -1-benzyl-N, 4-dimethylpiperidine-3-amine dihydrochloride and isomer thereof | 江苏晶立信医药科技有限公司 | 2022-11-04 | — | — | CN | claimed |
| CN-111574522-B | Synthesis method of tofacitinib key intermediate | 杭州华东医药集团浙江华义制药有限公司 | 2021-11-23 | — | — | CN | claimed |
| CN-111574522-A | Synthesis method of tofacitinib key intermediate | 杭州华东医药集团浙江华义制药有限公司 | 2020-08-25 | — | — | CN | claimed |
| CN-121378106-A | Tofacitinib citrate preparation method of intermediate | 江苏威奇达药业有限公司 | 2026-01-23 | — | — | CN | disclosed |
| CN-121164475-A | Analytical method for determining enantiomer and diastereoisomer of (3R, 4R) -1-benzyl-N, 4-dimethylpiperidin-3-amine dihydrochloride | 江苏艾立康医药科技有限公司 | 2025-12-19 | — | — | CN | disclosed |
| CN-121164475-A | Analytical method for determining enantiomer and diastereoisomer of (3R, 4R) -1-benzyl-N, 4-dimethylpiperidin-3-amine dihydrochloride | 江苏艾立康医药科技有限公司 | 2025-12-19 | — | — | CN | disclosed |
| EP-4656249-A2 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | Daewoong Pharmaceutical Co., Ltd. (KR) | 2025-12-03 | — | — | EP | disclosed |
| CN-119574716-A | Method for detecting impurities in (3R, 4R) -1-benzyl-N, 4-dimethylpiperidin-3-amine dihydrochloride | 南京药石科技股份有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119574716-A | Method for detecting impurities in (3R, 4R) -1-benzyl-N, 4-dimethylpiperidin-3-amine dihydrochloride | 南京药石科技股份有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119574716-A | Method for detecting impurities in (3R, 4R) -1-benzyl-N, 4-dimethylpiperidin-3-amine dihydrochloride | 南京药石科技股份有限公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-3327021-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | Yangji Chemical Co., Ltd. (KR) | 2018-05-30 | — | — | EP | disclosed |
| CN-107064350-A | Method for detecting suspected genotoxic impurity of tofacitinib citrate | 山东裕欣药业有限公司 | 2017-08-18 | — | — | CN | disclosed |
| EP-1913000-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES; THEIR INTERMEDIATES AND SYNTHESIS | PFIZER PROD INC (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110288297-A1 | Pyrrolo[2,3-d]Pyrimidine Derivatives; Their Intermediates and Synthesis | PFIZER, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2324020-A2 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010014930-A2 | THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | ACHE 4871/4885BCHE 4767/4885SCN4A 2205/4885 |
| US-20110288297-A1 | Pyrrolo[2,3-d]Pyrimidine Derivatives; Their Intermediates and Synthesis | DPYD, CPS1, TYMS | ACHE 4478/4885BCHE 4680/4885SCN4A 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.